Targazyme, Inc. Announces Receipt of an SBIR Award From the National Institute of Dental and Craniofacial Research for the Development of TZ101 Treated Mesenchymal Stem Cells for Treatment of Oral Muc

Targazyme, Inc. , a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund the development of genetically-modified mesenchymal stem cells treated with Targazyme's lead product, TZ101 for ... (more)

http://ift.tt/1vO0XtT